title: Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2.
abstract: Paraoxonases (PONs) are a family of proteins that may play a significant role in providing relief from both toxic environmental chemicals as well as physiological oxidative stress. Although the physiological roles of the PON family of proteins, PON1, PON2, and PON3, remain unknown, epidemiological, biochemical, and mouse genetic studies of PON1 suggest an anti-atherogenic function for paraoxonases. To determine whether PON2 plays a role in the development of atherosclerosis in vivo, we generated PON2-deficient mice. When challenged with a high fat, high cholesterol diet for 15 weeks, serum levels of high density lipoprotein cholesterol, triglycerides, and glucose were not significantly different between wild-type and PON2-deficient mice. In contrast, serum levels of very low density lipoprotein (VLDL)/low density lipoprotein (LDL) cholesterol were significantly lower (-32%) in PON2-deficient mice compared with wild-type mice. However, despite lower levels of VLDL/LDL cholesterol, mice deficient in PON2 developed significantly larger (2.7-fold) atherosclerotic lesions compared with their wild-type counterparts. Enhanced inflammatory properties of LDL, attenuated anti-atherogenic capacity of high density lipoprotein, and a heightened state of oxidative stress coupled with an exacerbated inflammatory response from PON2-deficient macrophages appear to be the main mechanisms behind the larger atherosclerotic lesions in PON2-deficient mice. These results demonstrate that PON2 plays a protective role in atherosclerosis.
authors.affiliation: Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA.
authors.forename: Carey J
authors.initials: CJ
authors.lastname: Ng
authors.forename: Noam
authors.initials: N
authors.lastname: Bourquard
authors.forename: Victor
authors.initials: V
authors.lastname: Grijalva
authors.forename: Susan
authors.initials: S
authors.lastname: Hama
authors.forename: Diana M
authors.initials: DM
authors.lastname: Shih
authors.forename: Mohamad
authors.initials: M
authors.lastname: Navab
authors.forename: Alan M
authors.initials: AM
authors.lastname: Fogelman
authors.forename: Aldons J
authors.initials: AJ
authors.lastname: Lusis
authors.forename: Stephen
authors.initials: S
authors.lastname: Young
authors.forename: Srinivasa T
authors.initials: ST
authors.lastname: Reddy
mesh_terms: D000818:Animals; D001055:Apolipoproteins B / Q000378:metabolism*; D043303:Aryldialkylphosphatase / Q000172:deficiency* / Q000235:genetics / Q000502:physiology*; D050197:Atherosclerosis / Q000201:enzymology* / Q000235:genetics / Q000517:prevention & control*; D002460:Cell Line; D004195:Disease Models, Animal; D005260:Female; D008077:Lipoproteins, LDL / Q000737:chemistry / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000737:chemistry / Q000378:metabolism*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout
chemical_list: D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D043303:Aryldialkylphosphatase